Company Overview and News

0
XPLR / Xplore Technologies Corp. SC 14D9

18h sec.gov
SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
XPLR

2
Zebra Technologies to Buy Xplore Technologies for $90M

2018-07-06 zacks
Zebra Technologies Corporation (ZBRA - Free Report) yesterday announced that it will acquire all the shares of Xplore Technologies Corp. (XPLR - Free Report) . The acquisition, to be accomplished through a tender offer, has been approved by the boards of directors of the companies. Austin, TX-based Xplore Technologies primarily engages in manufacturing 2-in-1 laptops, rugged mobile computers (semi, fully and ultra rugged) and accessories.
XPLR FSCT ZBRA

49
XPLR / Xplore Technologies Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-05 fintel.io
Xplore Technologies Corp. (NASDAQ:XPLR) has 41 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,969,856 shares. Largest shareholders include Phoenix Venture Fund LLC, Merriman Wealth Management, LLC, Royal Bank Of Canada, Vanguard Group Inc, Renaissance Technologies LLC, AWM Investment Company, Inc.
XPLR RY RY VRX RY.PRSCL RY.PRS ZBRA RBCDF SLXP RY.PRT PGNX

1
Are Xplore Shareholders Getting Enough in the Buyout?

2018-07-05 247wallst
Xplore Technologies Corp. (NASDAQ: XPLR) shares spiked on Thursday after it was announced that the company would be acquired by Zebra Technologies Corp. (NASDAQ: ZBRA). The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2018.
XPLR ZBRA

0
Xplore to be bought out by Zebra Technologies at a 48% premium - MarketWatch

2018-07-05 marketwatch
Xplore Technologies Corp. XPLR, +4.38% said Thursday it has agreed to be acquired by Zebra Technologies Corp. ZBRA, +0.03% in a deal that gives Xplore a market value of about $66.2 million. Xplore shares are halted until 8:30 a.m. ET, while Zebra shares were still inactive in the premarket. Under terms of the deal, Zebra will pay $6 in cash for each Xplore share outstanding, which represents a 48% premium to Tuesday closing price of $4.
XPLR ZBRA

1
Xplore Technologies' stock halted for news pending

2018-07-05 marketwatch
Global Paper Towel, Tissue Manufacturers Using Xplore Rugged Tablets to Extend Life of Production Line Equipment
XPLR

0
Xplore Technologies Reports 12% Revenue Growth, $0.03 EPS in Fiscal 2018

2018-07-05 globenewswire
AUSTIN, Texas, July 05, 2018 (GLOBE NEWSWIRE) -- Xplore Technologies Corp. (NASDAQ:XPLR), a global leader in rugged computing, today reported increased revenue and positive net income for its fiscal year 2018, ended March 31, 2018, and the signing of a definitive agreement to be acquired by Zebra Technologies.
XPLR ZBRA

0
Zebra Technologies to Acquire Xplore Technologies

2018-07-05 globenewswire
LINCOLNSHIRE, Ill. and AUSTIN, Texas, July 05, 2018 (GLOBE NEWSWIRE) -- Zebra Technologies Corporation (NASDAQ:ZBRA) and Xplore Technologies Corporation (NASDAQ:XPLR) today announced that their boards of directors have approved a definitive agreement in which Zebra will acquire all outstanding common stock of Xplore for $6.00 per share in cash. Under the terms of the agreement, Zebra plans to effect the acquisition via a tender offer.
XPLR PJT ZBRA

3
XPLR / Xplore Technologies Corp. NT 10-K

2018-06-29 sec.gov
UNITED STATES
XPLR

2
Xplore to File Form 12b-25, Postpones Announcement of Fiscal Year 2018 Results to July 5

2018-06-28 globenewswire
AUSTIN, Texas, June 28, 2018 (GLOBE NEWSWIRE) -- Xplore Technologies Corp. (NASDAQ:XPLR), a global leader in rugged computing, today announced that it intends to file a Form 12b-25 Notification of Late Filing with the U.S. Securities and Exchange Commission, postponing the filing of its Annual Report on Form 10-K for its fiscal year 2018 for up to 15 days. As a result, Xplore now intends to announce its financial results for the fiscal year 2018 fourth quarter and full year on Thursday, July 5, 2018, before the market opens.
XPLR

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 983950700